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Background: Systemic amyloidoses is a heterogeneous group of diseases either acquired or hereditary.
Amyloidoses can involve the gastrointestinal tract and the nature of the precursor protein that forms the fibrils
deposits should be identified to adjust the treatment and evaluate the prognosis. Lysozyme amyloidosis (ALys) is a
rare, systemic non neuropathic hereditary amyloidosis with a heterogenous phenotype including gastrointestinal,
renal and hepatic symptoms.
Case presentation: We report and describe symptoms and gastrointestinal tract involvement in a new family with
hereditary lysozyme amyloidosis. Clinical manifestations and organ involvement of nine affected members of a new
family with the p.Trp82Arg ALys variant were recorded. All affected individuals suffered with prevailing
gastrointestinal symptoms leading to the diagnosis of ALys. 8/9 had non specific upper gastrointestinal symptoms
and 3/9 had rectocolic inflammation evoking inflammatory bowel disease. No other organ involvement by
amyloidosis was found. Histological examination revealed amyloid deposits in all cases and all carried the p.Trp82Arg
ALys variant at a heterozygous state.
Conclusion: Hereditary amyloidosis associated with the p.Trp82Arg lysozyme variant in this new family is predominantly
associated with mild upper gastrointestinal tract involvement and in some cases with inflammatory bowel disease.
Amyloidosis should be considered in atypical or treatment resistant, upper or lower chronic gastrointestinal symptoms.
When associated with a familial history a lysozyme gene mutation must be searched.
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Systemic amyloidoses is characterized by deposition of
protein in an abnormal fibrillary conformation leading
to disruption of tissues and potential organ dysfunction.
Systemic amyloidoses can be either acquired or heredi-
tary. Acquired amyloidosis, mainly related to AA and AL
amyloidosis, should be distinguished from hereditary neuro-
pathic and non-neuropathic systemic amyloidosis. Lysozyme
amyloidosis (ALys) belongs to the group of hereditary non-
neuropathic systemic amyloidoses, firstly described in 1932* Correspondence: nicolas.schleinitz@ap-hm.fr
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unless otherwise stated.by Ostertag [1] with the identification of the lysozyme vari-
ant performed in 1993 by Pepys et al. [2] (Online Mendelian
Inheritance in Man 153450). Until now eight pathogenic
mutations of the lysozyme gene (LYZ) have been reported
[2-8]. All are inherited in an autosomal dominant fashion.
ALys phenotype is heterogeneous and includes gastrointes-
tinal (GI) symptoms, hepatic rupture, sicca syndrome, pur-
pura, renal failure and lymphadenopathy. We report here a
new large family in which the p.Trp82Arg variant (this no-
menclature includes the 18 amino acid signal peptide
according to Human Genome Variation Society guide-
lines, http://www.hgvs.org/mutnom// and p.Trp82Arg
corresponds to the previous Trp64Arg variant) was foundd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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involvement of these 9 affected members.Case presentation
The proband
The proband (III 6 in the family tree in the Figure 1)
was a 51-year-old woman, from italian origin, with a
longstanding history of gastric pain and symptoms of
gastro esophageal reflux. She also complained of chronic
cough. Previous upper endoscopies reported erythema-
tous gastritis without helicobacter pylori infection and a
bulbar ulcer. She was treated by proton pump inhibitors
without success. One month later, control upper endos-
copy showed persistent erythematous gastritis and biop-
sies revealed abnormal mucosal deposits characterized
by positive Congo red stain with the pathognomonic bi-
refringence under polarize light evoking amyloidosis. The
patient also reported ocular and oral sicca syndrome and
clinical examination revealed mild hepatomegaly. Neuro-
logical examination was normal. Serum protein electro-
phoresis and serum free light chains analysis excluded a
monoclonal gammapathy and C reactive protein was nor-
mal. The patient had no proteins in the urine, urine blood
casts and blood creatinin level were both normal.
On thoraco-abdominal CT-scan, only multiple in-
flammatory infracentimetric and centrimetric mesen-
teric lymph nodes with homogeneous hepatomegalyFigure 1 Pedigree of the ALys family with gastrointestinal manifestat
with a left green half-square or half-circle. Individuals with white square or
half-circle presented with gastrointestinal amyloidosis deposits on pathologwere noted. Echocardiography was normal. Genomic
DNA analysis of the LYZ gene revealed a heterozygous
single base-pair mutation (T to A substitution, TGG/
AGG) in the codon 82 of exon 2 leading to the change of
the amino acid from tryptophan to arginine (p.Trp82Arg
in the new nomenclature, corresponds to the previously
called Trp64Arg variant). After 4 years of follow up, the
patient remained stable.Kindred
Clinical, biological, morphological and histological find-
ings of the patient’s were then recorded.
Clinical, biological, morphological and histological find-
ings of the patient’s were recorded prospectively or retro-
spectively. Gene analysis was part of standard care and
was proposed to all the family’s member after obtaining
their informed and written consent. This retrospective
and descriptive study required no additional investigation
to standard care and therefore did not require a specific
statement of our ethical committee. All the patients were
seen for physical examination in our clinical center and
written consent was obtained for publication of the data.Histology and immunohistochemistry
Tissue biopsies, when available, were analyzed with the
classical Congo red stain for amyloid deposits. Immuno-
histochemistry was only performed on the proband’sion. Subjects with the identification of the Alys mutation are shown
circle were not analyzed. Patients with a right green half-square or
ical analysis by red Congo staining.
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tein, kappa and anti lambda light chains and against
lysozyme protein. Irrelevant monoclonal antibody and
normal immunoglobulins were used as controls.
Tissues were obtained for 7 patients; five gastric biop-
sies, 4 colic biopsies and one gall-bladder, as showed in
the family tree (Figure 1). All gastric biopsies and 3 of 4
colic biopsies showed amyloid deposits on red Congo
stains. The gallbladder obtained after surgery for gallstones
in patient IV4 showed also amyloid deposits in the gall-
bladder walls with the red Congo stain. Immunohisto-
chemistry for amyloidosis typing was done only for the
proband because of the unavailability of specific antibodies
to Lyzozyme in all centers.
DNA analysis
Genomic DNAs were extracted from peripheral blood
leukocytes by a standard procedure after informed con-
sent of the available family members. The five exons and
flanking introns of the lysozyme gene were amplified by
the polymerase chain reaction (PCR) using previously
published primers and conditions [3]. Each PCR product
was directly sequenced on both strands using a dye ter-
minator cycle sequencing kit (Perkin Elmer, Norwalk,
CT, USA) and the sequencing products were resolved on
an automatic fluorescent DNA sequencer ABI Prism 377
(Applied Biosystems, Valencia, CA, USA). The nucleo-
tide sequences of each exon were then compared with
the published sequence of the lysozyme cDNA and the
identified mutation was numbered according to the pub-
lished cDNA sequence [4].Table 1 Patients clinical and gastroenterological findings
Patient
(gender)
GI*symptoms Age at diagnosis
(years)
Upper GI tract finding
(pathological findings)
II 1 (F) Heartburn 71 Peptic esophagitis Esophag
Papilloma Non haemorrha
gastritis Duodenum divertic
(Duodenal and antrum amylo
plus antrum atrophy)
III 2 (M) Heartburn 41 (Gastric amyloidosis)
III 6 (F) Heartburn Nausea
Dyspepsia GOR**
51 Erythematous gastritis, Bul
ulcer. (Gastric amyloidosis
III 9 (F) Rectal hemorrhage
Diarrhea
46 Erythematous gastritis, Antr
ulcer (Gastric and duoden
amyloidosis)
IV 2 (F) Heartburn 28 -
IV 3 (F) Heartburn 33 -
IV 4 (F) Heartburn 34 Gastric ulcer
IV 5 (M) Heartburn 24 Erythematous and atroph
gastritis (Gastric amyloidos
IV 7 (F) Abdominal pain
Rectal hemorrhage
27 (Gastric amyloidosis)
*Gastro intestinal (GI) ; **Gastroesophageal reflux (GOR); #proton pump inhibitors (PPI); §MNine subjects of the kindred (not including the pro-
band) accepted after informed consent to be screened
for the ALys mutation. Sequence analysis of lysozyme
exon 2 revealed a heterozygous single base-pair transi-
tion from T to A of the first nucleotide position of
codon 82 (TGG/AGG), in 9/10 tested members. This
nucleotide substitution modifies the amino acid at pos-
ition 82 in the mature protein from tryptophane to ar-
ginine. p.Trp82Arg in the new nomenclature, wich was
previously called Trp64Arg variant).
Kindred clinical presentation
Both parents of the proband were born in the Piedmont re-
gion in Italy (without known consanguinity). Her mother
(II2) died aged of 52 years from meningeal hemorrhage
and was not known to have gastrointestinal tract symp-
toms. The proband’s father was still in good health. The
cause of death of her maternal grandmother (I2) and
grandfather (I1) was unknown. The first symptoms, the
clinical manifestations, the results of digestive investiga-
tions and follow-up of the 9 affected members of this fam-
ily (including the proband) are shown in Table 1. All
presented with GI symptoms. The most frequent symptom
was heartburn related to endoscopic findings of non spe-
cific gastritis, ulcers (antral or bulbar) or oesophagitis. In
all patients with endoscopic evaluation (7/9) typical amyl-
oid deposits were shown on gastric or duodenal tissue bi-
opsies with the red Congo staining. Interestingly, three
members of this family had the diagnosis of inflammatory
bowel disease: a proband’s sister (III9) who complained of
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the diagnosis of ulcerative colitis. She was treated with
mesalazine. She also had chronic erythematous gastritis
and colon polyps. In biopsies, amyloid deposits were ob-
served in stomach and duonenum and in rectocolic biop-
sies. The second was a 27-year old woman (IV7) who
presented with a history of abdominal pain and rectal
hemorrhage with pancolitis leading to the diagnosis of ul-
cerative colitis. She improved under mesalazine. The third
was a 24-year-old man who presented ileal ulcers on lower
endoscopy suggesting the diagnosis of inflammatory bowel
disease (IV5), biopsies only revealed amyloid deposits on
ileal and colic biopsies without inflammatory lesions.
Moreover, erythematous gastritis was noted on upper en-
doscopy with amyloid depositis in the antrum. Magnetic
resonance imaging of ileon and fecal calprotectin were
both normal. Three of the proband’s daughters were af-
fected, all complained of gastro esophageal reflux symp-
toms. One of these suffered from gastric ulcer (IV4) and
had surgery for gallstones at age 37. Typical amyloid de-
posits were found in her gall-bladder mucosa. The half-
sister of the proband’s mother (II1) and his son (III2) were
also affected. The 71-year-old aunt of the proband (II1)
presented with a long history of gastro esophageal reflux
symptoms and sicca syndrome. Iterative upper endoscopies
noted peptic esophagitis, non hemorrhagic gastritis, an-
trum atrophy and duodenum diverticulitis. Amyloid depos-
itis were found in the antrum and duodenal biopsies.
Lower gastrointestinal tract endoscopy showed colon tubu-
lar polyposis and amyloid deposits. His son aged 41 (III2)
presented only gastro esophageal reflux symptoms without
gastritis on upper endoscopy. However, amyloid deposits
were noted in the stomach. All the affected patients had
normal echocardiography, normal kidney function, no in-
flammatory biological state, negative proteinuria and nor-
mal urine blood casts. None presented with neurological
symptoms or abnormal neurological evaluation. All af-
fected patients were alive with five years of follow up. Of
note another sister (III4) and brother (III7) were known to
have had chronic pancreatitis but they refused genetical
testing. No further information could be obtained for II3,
III5, III8 and III10.
Conclusions
This new family of hereditary ALys associated with the
p.Trp82Arg variant is of particular interest because the
clinical manifestations were limited to the gastrointes-
tinal tract with some affected individuals presenting with
inflammatory bowel disease. Lysozyme is an hydrolytic
enzyme mainly produced by liver, the digestive tract and
by macrophages [5]. ALys deposits in affected patients
have been found in gastrointestinal tract, liver, spleen, ad-
renal glands, muscles, vessels, lymph nodes, bone marrow
and gallbladder [2-4,6-9]. All affected individuals of thiskindred complained of variable gastric pain and symptoms
of gastro esophageal reflux. This confirms that ALys is
very penetrant. The upper gastrointestinal tract endo-
scopic findings were unspecific in all affected patients
showing erythematous gastritis with or without atrophy or
gastric/bulbar ulcer, observed only in some patients. The
symptoms were poorly improved by proton pump inhibi-
tors. These upper gastrointestinal tract symptoms have
already been reported in most of patients with ALys
[4-11] and are probably related, as sicca syndrome, to the
local production and deposit of the abnormal lysozyme pro-
tein. None of the patients of the kindred, even with long-
standing symptoms, presented with digestive hemorrhage
related to gastric ulcers. Only the systematic complementary
analysis of the biopsies for amyloid deposits with the Congo
red stain revealed the gastrointestinal tract amyloidosis. Be-
cause upper gastrointestinal tract manifestation can be rela-
tively mild and non specific, as in this family, ALys is
probably under diagnosed. This is illustrated by case II1 in
whom the diagnosis, suggested by the discovery of ALys in
the proband, was made at age 71 after numerous upper
gastrointestinal tract endoscopies. Thus in cases of chronic
gastritis or ulcers and a poor response to proton pump in-
hibitors, gastrointestinal tract amyloidosis should be evoked,
and searched systematically on biopsies by red Congo stain-
ing. If positive and in case of a familial history patients
should be screened for ALys. This can be done by immuno-
histochemistry with an anti lysozyme antibody and con-
firmed by DNA analysis.
Interestingly, three patients of the kindred were treated
for inflammatory bowel disease and were found to have
colonic ALys deposits. Two of them reported proctorrha-
gia. This suggests that ALys colonic amyloidosis, already
reported in previous patients with ALys amyloidosis [5],
could predispose to or mimic inflammatory bowel dis-
ease. This should be distinguished from rare reports of
systemic AA amyloidosis secondary to inflammatory
bowel disease [10].
In other type of amyloidosis, gastrointestinal tract in-
volvement is very common but is often subclinical and
the typical clinical presentations are also mostly nonspe-
cific. They can present with macroglossia as observed in
AL amyloidosis, hemorrhage, motility disorders, disturb-
ance of bowel habit and malabsorption. Endoscopic and
radiological features are also nonspecific, with the small
intestine most commonly affected [12]. They can be dis-
tinguished by the analysis of the amyloid deposits on im-
munochemistry, the search of genetic variant associated
with hereditary amyloidosis or pathologies associated
with the acquired AA or AL amyloidosis.
Besides the gastrointestinal tract ALys can affect liver.
Only the proband presented with mild hepatomegaly but
the familial history noted no liver complications as
hemorrhage or rupture as reported in previous families
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similar in affected individuals; there are heterogenous
symptoms between different families of ALys but the
clinical prentation seem to be homogenous in the same
family.
Other manifestations of ALys were not presented by
these family members except a sicca syndrome. It was
present in the two most aged patients of this kindred as in
6/9 of previously reported patients with the W64R variant.
ALys was not associated with clinical neurological or car-
diac involvement [3,4,6-8,15]. None of the patients of this
family presented with renal insufficiency or proteinuria.
Renal ALys amyloidosis was reported in patients with the
D67H, the F57I and in some patient with the W64R lyzo-
zyme variant. All the patients with the W64R variant and
renal amyloidosis came from the family with the T to A
substitution at codon 82. None of the patients from the
three families with the T to C substitution at codon 82
(including this family) had renal involvement suggest-
ing that other genetic factors are involved [15].
The families with the p.Trp82Arg variant already re-
ported are either from French genetic background or
from the Piedmont in Northern Italy. Two mutations at
codon 82 of exon 2 lead to this variant: a T to A substi-
tution (TGG/AGG) in three families of Italian origin
and a T to C substitution (TGG/CGG) in one other un-
related family from French origin. The mother of the
proband and her maternal grandparents were native
from the Piedmont in Northern Italy as four previous
families already reported [8]. Haplotype analysis has not
been performed to date to link these three apparently
unrelated families.
This new family of ALys, a form of hereditary non-
neuropathic amyloidosis, confirms that gastrointestinal
tract involvement is the most common manifestation of
the disease. This new family suggests that renal involve-
ment is uncommon in patient with the W64R variant.
Symptoms are unspecific and mostly related to upper
gastrointestinal tract involvement. For this reason we
suggest that in case of atypical gastrointestinal tract dis-
orders amyloidosis should be systematically searched by
red Congo staining on standard biopsies. In case of
amyloidosis and a familial history patients should be
screened for ALys.Consents
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